

DAFTAR PUSTAKA

- Abraldes JG, Garcia-Tsao G, Editorial: Simple clinical tools to predict decompensation in patients with compensated cirrhosis. An unmet need *Clinical Gastroenterology and Hepatology* (2019)
- Amaral AED, Rode MP, Cisilotto J, da Silva TE, Fischer J, Mاتيollo C *et al.* MicroRNA profiles in serum samples from patients with stable cirrhosis and miRNA-21 as a predictor of transplant-free survival. *Pharmacol Res.* 2018;134:179-192.
- Ambros V. The functions of animal microRNAs. *Nature.* 2004; 431:350–355.
- An FM, Yu DS, Xie Q, Gong BD, Wang H, Guo Q *et al.* The role of miRNA-122 expression during the acute liver failure in mice induced by D-GalN/LPS. *Zhonghua Gan Zang Bing Za Zhi* 2010; 18(7): p. 527-32
- Arataki K, Hayes CN, Akamatsu S, Akiyama R Abe H, Tsuge M, *et al.* Circulating Micro RNA-22 Correlates with MicroRNA-122 and Represents Viral Replication and Liver Injury in Patients with Chronic Hepatitis B. *J. Med. Virol* 2013. 85:789–798.
- Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. *J Hepatol* 2019; 70: 151–71.
- Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI. Riset Kesehatan Dasar 2013. Jakarta: Kementerian Kesehatan RI; 2013.
- Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR 122 – A key factor and therapeutic target in liver disease. *J Hepatol* 2015;62:448–457
- Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Croce LS, Mazzoran L *et al.* Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. *Gut* 1999;44:874–80
- Bellentani S, Saccoccio G, Costa G, Tribelli C, Manenti F, Sodde M, *et al.* The Dionysos Study Group. Drinking habits as cofactors of risk for alcohol induced liver damage. *Gut* 1997;41:845–50.
- Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. *J Hepatol* 2015;63:1272–84

- Biggins, S. W., Kim, W. R., Terrault, N. A., Saab, S., Balan, V., Schiano, T *et al* (2006). Evidence-Based Incorporation of Serum Sodium Concentration Into MELD. *Gastroenterology*, 130(6), 165-60.
- Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, Shi Y, *et al*. Serum miR 122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. *Am. J. Gastroenterol*. 2011; 106:1663–1669
- Cheng JL, Zhao H, Yang SG, Chen EM, Chen WQ, Li JL. Plasma miRNA-122-5p and miRNA-151a-3p identified as potential biomarkers for liver injury among CHB patients with PNALT. *Hepatology Int*. 2018. Mei; 12(3):277-287.
- Cholongitas E, Papatheodoris G.V., Vangeli M., Terreni N., Patch D and Burroughs A.K. Systematic review: the model for end-stage liver disease – should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis?. *Aliment Pharmacol Ther* 2005; 22: 1079–1089
- Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. *J Clin Gastroenterol* 2006; 40 (3 Suppl 1):S5–10.
- Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HL, Chan HL. The role of quantitative hepatitis B surface antigen revisited. *J Hepatology* 2017; 66:398–411.
- D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatology* 2006; 44:217–231.
- de Franchis R. Evolving consensus in portal hypertension report of the baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. *J Hepatology* 2005; 43:167–176.
- Ehrmann J, Galuszková D, Ehrmann J, Krc I, Jezdinská V, Vojtěšek B, *et al*. Apoptosis-related proteins, BCL-2, BAX, FAS, FAS-L and PCNA in liver biopsies of patients with chronic hepatitis B virus infection. *Pathol Oncol Res* 2000; 6: 130-135
- European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J Hepatology*. 2010 ; 53: 397–417
- European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. *J Hepatology* 2017; 67 : 370–398
- European Association for the Study of the Liver. EASL clinical practice guidelines on the management of patients with decompensated cirrhosis. *J hepatology* 2018; <https://doi.org/10.1016/j.jhep.2018.03.024>
- Garcia G, Tsao MD. The Child-Turcotte Classification: From Gestalt to Sophisticated Statistics and Back. *Dig Dis Sci*. 2016 November ; 61(11): 3102–3104

Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. *N Engl J Med* 2010;362: 823–832

Gines P, Quintero E, Arroyo V. Compensated cirrhosis: natural history and prognosis. *Hepatology* 1987;7:122–128

Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. MiR 122, a paradigm for the role of microRNAs in the liver. *J Hepatol* 2008;48:648–656.

Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H *et al.* Essential metabolic, antiinflammatory, and anti-tumorigenic functions of miR 122 in liver. *J. Clin. Invest.* 2012; 122:2871–83.

Instalasi Catatan Medik (ICM) RSUP dr Sardjito, 2019.

Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL *et al.* A model to predict survival in patients with end-stage liver disease. *Hepatology* 2001 Feb; 33(2): 464–70.

Kaplan DE, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, *et al.* Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database. *Clin Gastroenterol Hepatol.* 2015 Dec; 13(13):2333–2341.

Kennedy PT, Sandalova E, Jo J, Gill U, Ushirolumb I, Tan AT, *et al.* Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. *Gastroenterology* 2012;143:637–645

Krauskopf J, de Kok TM, Schomaker SJ, Gosink M, Burt DA, Chandler P, *et al.* Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human. *PLoS ONE* 2017 12(5):e0177928.

Kusumobroto, H.O Sirosi Hati dalam Buku Ajar Penyakit Hati Edisi I. 2012 Jakarta CV Sagung Seto Hal 347-8

Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, Johnson JM, *et al.* Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. *Clin Chem* 2009; **55**: 1977-1983

Lee RC, Feinbaum RL, Ambros V. The *C. elegans* Heterochronic Gene *lin-4* Encodes Small RNAs with Antisense Complementarity to *lin-14*. *Cell*, 1993;75:843-854

Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan J *et al.* miR 122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. *J. Hepatol.* 2013; 58 (3):522–528

Livax KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using RealTime Quantitative PCR and the 2^{-ΔΔCq} Method. *ANALYSIS OF RELATIVE GENE EXPRESSION DATA USING REALTIME QUANTITATIVE PCR AND THE 2^{-ΔΔCq} METHOD. METHODS* 25;2001:402–408.

Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA—The holy grail to hepatitis B cure. *J Hepatol* 2016;64:S41 –S48

- Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. *Hepatology* 2000; 31: 864–71
- Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, *et al.* HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. *Gastroenterology* 2016;151 :986–998
- Nakamura M, Kanda T, Jiang X, Haga Y, Takahashi K, Wu S,*et al.* Serum microRNA-122 and Wisteria flribunda agglutinin-positiveMac-2 binding protein are useful tools for liquid biopsy of the patientswith hepatitis B virus and advanced liver firosis. *PLoS One.* 2017;12(5)
- Nurdjanah S. Sirosis hati. In: Sudoyono AW, Setiyohadi B, Alwi I, K. MS, Setiati S, editors. Buku ajar ilmu penyakit dalam. Jakarta: Interna Publishing. 2009. p. 668-73
- Perhimpunan Peneliti Hati Indonesia. Konsensus Nasional Penatalaksanaan Hepatitis B. 2017:1-2.
- Sani MRM, Asgharzade S, Alghasi A, Boroujeni AS, Sadati SJA, Moradi MT. MicroRNA-122 in patients with hepatitis B and hepatitis B virus-associated hepatocellular carcinoma. *J Gastrointest Oncol* 2019;10(4):789-796
- Schoof CR, Botelho EL, Izzotti A, Vasques Ldos R. MicroRNAs in cancer treatment and prognosis.*nAm. J. Cancer. Res.* 2012; 2:414–433
- Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. *Hepatology* 1988;8:1151–1157
- Schuppan D, Afdhal NH. Liver Cirrhosis. *Lancet.* 2008 March 8; 371(9615): 838–851.
- Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. *Virology* 2015;479–480:672–686.
- Sepanlau SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M *et al.* GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol.* 2020;5(3):245-266. doi:10.1016/S2468 1253(19)30349-8
- Shi Liyu, Zheng Xiaoqiu, Fan Yuzhuo, Yang Xiaolan, Li Aimei and Qian Jun. The contribution of miR 122 to the innate immunity by regulating toll-like receptor 4 in hepatoma cells. *BMC Gastroenterology* (2019) 19:130
- Sun G, Yan J, Noltner K, Feng J, Li H, Sarkis DA *et al.* SNPs in human miRNA genes affect biogenesis and function. *RNA.* 2009; 15(9):1640–51

- Szabo G, Bala S. MicroRNAs in liver disease *Nat Rev Gastroenterol Hepatol*. 2013 September ; 10(9): 542–552
- Tambunan A, Mulyadi Y, Kahtan MI. Karakteristik pasien sirosis hati di RSUP Dr. Soedarso Pontianak periode Januari 2008 - Desember 2010. *Jurnal Mahasiswa PSPD FK Universitas Tanjungpura*. 2013;2(1):1-19.
- Tapper EB, Zhang P, Garg R, Nault T, Leary K, Krishnamurthy V *et al*. Body composition predicts mortality and decompensation in compensated cirrhosis patients: A prospective cohort study. *JHEP Rep*. 2020;2:100061
- Trebicka J, Anadol E, Elfiova N, Strack I, Roggendorf M, Viazov S, *et al*. Hepatic and serum levels of miR 122 after chronic HCV induced fibrosis. *J Hepatol*. 2013; 58(2):234-9.
- Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R *et al*. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. *J. Clin. Invest*. 2012; 122(8):2884–97.
- Waidmann O., Koberle V., Brunner F., Zeuzem S., Piiper A., Kronenberger B., Serum microRNA-122 predicts survival in patients with liver cirrhosis, *PLoS One* 2012; 7:9
- Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L *et al*, Loss of MicroRNA 122 Expression in Patients with Hepatitis B Enhances Hepatitis B Virus Replication Through Cyclin G1-Modulated P53 Activity. *Hepatology* 2012;55(3):730-41
- Wang WJ, Lai RT, Lu J, Xiang XG, Zhao GD, Tang WL *et al*. Correlation between circulating miR 122 and prognosis of chronic HBV-related liver failure. *J Dig Dis*. 2016;17(5):334-339.
- Wiese S, Hove JD, Bendtsen F, Moller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. *Nat Rev Gastroenterol Hepatol* 2014;11:177–186.
- Wu Y, Gao C, Cai S, Xia M, Liao G, Zhang X, *et al*. Circulating miR 122 Is a Predictor for Virological Response in CHB Patients With High Viral Load Treated With Nucleos(t)ide Analogs. *Front. Genet*. 2012 10(243):1-7.
- Xu J, Wu C, Che X, Wang L, Yu D, Zhang T *et al*. Circulating microRNAs, miR-21, miR 122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. *Mol. Carcinog*. 2011; 50:136–142.
- Yen Y-H, Huang CF, Huang CI, Holmes JA, Hsieh MH, Tsai YS *et al*. MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin. *Sci. Rep*. 2016;6, 33816.
- Zhai X, Cheng F, Ji L, Zhu X, Cao Q, Zhang Y *et al*. Leptin reduces microRNA-122 level in hepatic stellate cells in vitro and in vivo. *Mol Immunol*. 2017; 92:68-75
- Zhang H, Li Q, Guo Z, Guan Y, Du J, Lu Y, *et al*. Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B. *World J Gastroenterol* 2012 October 7; 18(37): 5188-5196



UNIVERSITAS
GADJAH MADA

Potensi Mikro Rna 122 Sebagai Penanda Kejadian Sirosis Dekompensasi Pada Pasien Dengan Latar

Belakang Infeksi Virus Hepatitis B Kronik Di RSUP Dr Sardjito Yogyakarta

NURAI DA WISUDANI, Dr.dr.Neneng Ratnasari SpPD-KGEH, dr.Putut Bayupurnama SpPD-KGEH

Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, Fei M, Sun S. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. *Clin Chem* 2010;56: 1830-1838

